arrow
O

Olivia Le Saux

centre de recherche en cancerologie de lyon
H指数:18
被引数:1,161

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Compartmentalized cytotoxic CD4+ T cell responses in anti-Yo paraneoplastic cerebellar degeneration

抗Yo副肿瘤小脑变病中隔化的CD4+ T细胞毒反应

2026-09-010
OAAI
Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study)

免疫检查点抑制剂再挑战在宫颈癌和子宫内膜癌中的疗效与安全性:一项多中心回顾性研究(RICE研究)

2026-07-150
PRE
French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025:Management of high-grade ovarian epithelial cancer (vol 113, pg 191, 2026)

法国临床实践指南,尼斯/圣保罗-德-旺斯 2024-2025:高级别卵巢上皮癌的管理(第 113 卷,第 191 页,2026 年)

2026-05-010
PRE
FIMBRIMENOP-2402 Trial: Evaluating Fimbriectomy with Delayed Oophorectomy in High-Risk Tubo-Ovarian Cancer Patients.

FIMBRIMENOP-2402试验:评估输卵管切除联合延迟卵巢切除术在高风险输卵管-卵巢癌患者中的应用

2026-04-180
PRE
Rethinking ovarian cancer III: the past decade and future directions

重新思考卵巢癌III:过去十年及未来方向

2026-04-130
PRE
French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of high-grade ovarian epithelial cancer

法国临床实践指南,尼斯/圣保罗-德旺斯 2024-2025:高级别卵巢上皮癌的管理

2026-02-011
PRE
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

转移性子宫内膜癌患者中分子分型与总生存期的关联:UTOLA II期GINECO试验的辅助结果。

2025-11-210
PRE
Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy

子宫内膜癌的免疫景观和肿瘤相关巨噬细胞密度:对免疫检查点抑制剂疗效的启示

2025-08-080
OA
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

帕博利珠单抗和伏立诺他联合治疗复发性/转移性鳞状细胞癌的疗效:一项II期篮式试验

2025-06-300
OAAI
Tumor–stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial

原发性肿瘤中肿瘤-基质比例作为接受化疗-免疫疗法作为一线治疗的晚期卵巢癌患者的预后生物标志物:NeoPembrOV/GINECO II期随机试验的分析

2025-06-010
OA
Ovarian Clear Cell Carcinoma: Prognostic And Predictive Factors. A Multicenter Retrospective Study

卵巢透明细胞癌:预后与预测因素。一项多中心回顾性研究

2025-02-010
PRE
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study

度伐利尤单抗和特瑞普利单抗与常规口服长春瑞滨联合治疗复发性晚期宫颈癌:一项开放标签的I/II期研究

2025-01-071
OA
Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials

通过模拟CA-125 KELIM评估肿瘤原发性化疗敏感性,以预测接受新辅助化疗和免疫治疗治疗的卵巢癌患者完全间隔减瘤术(IDS)的作用:一项GINEGEPS/GINECO研究,来自NeoPembrOv和INeOV试验

2024-09-010
PRE
Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?

免疫检查点抑制剂(ICIs)在错配修复缺陷(MMRd)的复发性/转移性子宫内膜癌(r/mEC)中表现出显著的临床获益(ECB):我们是否治愈了MMRd EC患者(pts)的一个亚群?

2024-09-010
PRE
PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
2024-08-260
OAAI
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
2024-07-162
OAAI
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma
2024-07-162
OAAI